PVCT Provectus Pharmaceutical Inc

OTC
$0.05

Provectus Pharmaceutical Inc (PVCT) is expected to report earnings on November 12, 2026, after the market close.

Provectus Pharmaceutical Reported Earnings
Thursday, August 13, 2026 · 12:00 AM ET
Earnings Date
Nov 12
Thursday · After Close
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Provectus Pharmaceutical Inc

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Sector

Healthcare